X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
As specified in the ALZ-101, an active, therapeutic oligomer-specific vaccine study protocol, the DSMB meets periodically to examine the safety data accumulated during progress of the study.
Lead Product(s): ALZ-101
Therapeutic Area: Neurology Product Name: ALZ-101
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Details:
Process optimisations have resulted in a more efficient and scalable manufacturing process enabling supply of ALZ-101, oligomer-specific vaccine in the amounts required for phase 2 clinical trials.
Lead Product(s): ALZ-101
Therapeutic Area: Neurology Product Name: ALZ-101
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2022
Details:
ALZ-101 is a vaccine that stimulates the production of antibodies against the toxic Aβ oligomers. Topline data of phase 1b study is anticipated in the second half of 2023.
Lead Product(s): ALZ-101
Therapeutic Area: Neurology Product Name: ALZ-101
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2021
Details:
ALZ-101 is a vaccine that stimulates the production of antibodies against the toxic Aβ oligomers. It has completed the preclinical phase. A first-in-human study in patients with early Alzheimer’s disease is about to start.
Lead Product(s): ALZ-101
Therapeutic Area: Neurology Product Name: ALZ-101
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2021
Details:
The monoclonal antibody, ALZ-201, which specifically targets amyloid Aβ42 oligomers, neutralises the neurotoxicity effect although it only targets a very small fraction of all amyloid Aβ.
Lead Product(s): ALZ-201
Therapeutic Area: Neurology Product Name: ALZ-201
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2021
Details:
The study design is today presented on a poster titled: First in Human study with ALZ-101, a unique and highly specific therapeutic vaccine against the neurotoxic oligomeric form of Aβ 1-42.
Lead Product(s): ALZ-101
Therapeutic Area: Neurology Product Name: ALZ-101
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
